---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-079997"
form_type: "8-K/A"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2022-03-21T23:59:59+00:00"
generated_at: "2026-06-26T21:29:36.423766+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adagio discloses additional compensation for Interim CEO Hering: $510K base, $7.5K monthly stipend

## Summary
- David Hering appointed Interim CEO on Feb 23, 2022 after Tillman Gerngross resigned as CEO and board member.
- Compensation approved Mar 18: base salary increased to $510,000 (eff. Feb 23) plus $7,500 monthly stipend during interim role.
- 2022 target bonus uses blended rate: 60% at assumed $600K salary for Interim CEO time, 40% at $410K for COO time.
- Tom Heyman reclassified from Class II to Class III director to rebalance board classes following Gerngross resignation.

## SEC filing metadata
- accession: 0001193125-22-079997
- form_type: 8-K/A
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2022-03-21T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312522079997/0001193125-22-079997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312522079997/d285779d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-079997
- JSON: https://secwatch.observer/filing/0001193125-22-079997.json
- Plain text: https://secwatch.observer/filing/0001193125-22-079997.txt

## Key facts
- Executive change
  David Hering was appointed as Interim Chief Executive Officer at Invivyd, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: Following Dr. Gerngross’s resignation, on February 23, 2022, the Board appointed David Hering to serve as Interim Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832038/000119312522079997/0001193125-22-079997-index.htm
- Executive change
  Tillman U. Gerngross resigned as Chief Executive Officer and President at Invivyd, Inc..
  - Action: resigned
  - Role: Chief Executive Officer and President
  source text: On February 23, 2022, Tillman U. Gerngross, Ph.D. resigned as Chief Executive Officer and President of Adagio Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832038/000119312522079997/0001193125-22-079997-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.